Edition:
United Kingdom

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

107.83USD
23 Apr 2018
Change (% chg)

$0.05 (+0.05%)
Prev Close
$107.78
Open
$108.51
Day's High
$109.67
Day's Low
$107.43
Volume
531,741
Avg. Vol
732,985
52-wk High
$149.17
52-wk Low
$96.18

Latest Key Developments (Source: Significant Developments)

Alexion To Acquire Wilson Therapeutics
Wednesday, 11 Apr 2018 

April 11 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION TO ACQUIRE WILSON THERAPEUTICS.SAYS ALEXION WILL ACQUIRE WILSON THERAPEUTICS THROUGH A TENDER OFFER.SAYS TOTAL EQUITY VALUE OF TRANSACTION AMOUNTS TO SEK 7,100 MILLION, OR APPROXIMATELY $855 MILLION.SAYS ALEXION INTENDS TO FINANCE ACQUISITION THROUGH CASH ON HAND..  Full Article

Abeona Therapeutics Appoints Carsten Thiel, Ph.D., As Chief Executive Officer
Monday, 2 Apr 2018 

April 2 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS APPOINTS CARSTEN THIEL, PH.D., AS CHIEF EXECUTIVE OFFICER.TIM MILLER CONTINUES AS PRESIDENT AND ASSUMES CHIEF SCIENTIFIC OFFICER ROLE.THIEL MOST RECENTLY SERVED AS EXECUTIVE VICE PRESIDENT AND CHIEF COMMERCIAL OFFICER OF ALEXION PHARMACEUTICALS, INC.  Full Article

Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study Of ALXN1210
Thursday, 15 Mar 2018 

March 15 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION ANNOUNCES POSITIVE TOP-LINE RESULTS SHOWING SUCCESSFUL PHASE 3 CLINICAL STUDY OF ALXN1210 IN COMPLEMENT INHIBITOR TREATMENT-NAÏVE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH).ALEXION PHARMACEUTICALS INC - SAFETY PROFILE OF ALXN1210 CONSISTENT WITH THAT SEEN FOR SOLIRIS.ALEXION PHARMACEUTICALS INC - REGULATORY SUBMISSIONS PLANNED IN UNITED STATES, EUROPEAN UNION, AND JAPAN IN SECOND HALF OF 2018.ALEXION PHARMACEUTICALS INC - SAFETY PROFILE OF ALXN1210 CONSISTENT WITH THAT SEEN FOR SOLIRIS.ALEXION PHARMACEUTICALS INC - ‍ALXN1210 ACHIEVED NON-INFERIORITY TO SOLIRIS ON CO-PRIMARY ENDPOINTS OF TRANSFUSION AVOIDANCE.ALEXION PHARMACEUTICALS INC - ‍ALXN1210 ACHIEVED ALL FOUR KEY SECONDARY ENDPOINTS​.ALEXION PHARMACEUTICALS INC - ‍ALXN1210 WAS GENERALLY WELL TOLERATED WITH A SAFETY PROFILE THAT IS CONSISTENT WITH THAT SEEN FOR SOLIRIS​.ALEXION PHARMACEUTICALS - ALXN1210 ALSO ACHIEVED NON-INFERIORITY TO SOLIRIS ON CO-PRIMARY ENDPOINTS OF LACTATE DEHYDROGENASE NORMALIZATION.  Full Article

Alexion Pharma Q4 GAAP Earnings Per Share $0.13
Thursday, 8 Feb 2018 

Feb 8 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS AND PROVIDES FINANCIAL GUIDANCE FOR 2018.Q4 NON-GAAP EARNINGS PER SHARE $1.48.Q4 GAAP EARNINGS PER SHARE $0.13.Q4 REVENUE ROSE 9.5 PERCENT TO $909.7 MILLION.SEES FY 2018 REVENUE $3.85 BILLION TO $3.95 BILLION.SEES 2018 GAAP EARNINGS PER SHARE‍​ $4.35 TO $4.75.SEES 2018 NON-GAAP EARNINGS PER SHARE $6.60 TO $6.80.ALEXION PHARMACEUTICALS - GAAP INCOME TAX EXPENSE FOR QUARTER INCLUDES $45.8 MILLION CHARGE RELATED TO U.S. TAX REFORM.SEES 2018 GAAP OPERATING MARGIN 31% TO 34%.SEES 2018 NON-GAAP OPERATING MARGIN 48% TO 49%.ALEXION SAYS 2018 GUIDANCE ASSUMES GAAP EFFECTIVE TAX RATE OF 15 - 17 PERCENT (INCLUSIVE OF CO'S PROVISIONAL ASSESSMENT OF U.S. TAX REFORM IMPACT).  Full Article

Alexion reports Q3 non-GAAP earnings per share of $1.44
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Alexion Pharmaceuticals Inc :Alexion reports third quarter 2017 results.Q3 non-GAAP earnings per share $1.44.Q3 GAAP earnings per share $0.35.Q3 revenue $859 million versus I/B/E/S view $864.5 million.Q3 earnings per share view $1.32 -- Thomson Reuters I/B/E/S.Alexion Pharmaceuticals Inc - ‍provides updated 2017 guidance​.Alexion Pharmaceuticals Inc sees ‍ 2017 total revenues $3,475 million to $3,525 million​.Alexion Pharmaceuticals Inc sees ‍ 2017 GAAP earnings per share $2.00 to $2.35​.Alexion Pharmaceuticals Inc sees ‍ 2017 non-GAAP earnings per share $5.50 to $5.65​.Alexion Pharmaceuticals Inc - ‍2017 guidance assumes Soliris revenue impact of $80 million to $90 million from ALXN1210, other clinical trial recruitments.Alexion Pharma - ‍plans to initiate Single, PK-based Phase 3 study of ALXN1210 delivered subcutaneously once/ week to support registration in PNH, aHUS​.FY2017 earnings per share view $5.60 -- Thomson Reuters I/B/E/S.FY2017 revenue view $3.52 billion -- Thomson Reuters I/B/E/S.  Full Article

Alexion Pharmaceuticals says U.S. FDA approves Soliris for treatment of patients with GMG
Tuesday, 24 Oct 2017 

Oct 23 (Reuters) - Alexion Pharmaceuticals Inc ::FDA approves soliris® (eculizumab) for the treatment of patients with generalized myasthenia gravis (gmg).  Full Article

Canada's PMPRB hearing panel issues decision in Soliris case
Wednesday, 27 Sep 2017 

Sept 27 (Reuters) - :Canada's Patented Medicine Prices Review Board hearing panel issues decision in Soliris case.Canada's PMPRB says panel found that the price of Soliris (Eculizumab) 10 mg/ml was and is excessive under sections 83 and 85 of the patent act.Canada's PMPRB says panel ordered Alexion to lower price of soliris in canada as of sept 20 to no higher than lowest price in 7 comparator countries.  Full Article

BRIEF-Alexion announces interim analysis from phase 3 open-label extension study of Soliris
Wednesday, 13 Sep 2017 

Adds company name in headline:Interim analysis from phase 3 open-label extension study shows sustained benefits of Soliris (Eculizumab) treatment for patients with refractory generalized myasthenia gravis.Says safety profile of Soliris was consistent with that observed in REGAIN study.Says ‍study is ongoing and planned to continue until January 2019​.Says ‍new results show sustained benefits across MG-specific assessment scales through additional 52 weeks for patients who continued to get Soliris​.Says benefits for patients treated with Soliris in REGAIN through 26 weeks were maintained in extension study across all four assessment scales.Says ‍safety profile of Soliris was consistent with that observed in REGAIN study​.Says benefits for patients treated with Soliris in REGAIN through 26 weeks were maintained in extension study.  Full Article

Interim analysis from phase 3 open-label extension study of Soliris
Wednesday, 13 Sep 2017 

Sept 13 (Reuters) - Alexion Pharmaceuticals Inc ::Interim analysis from phase 3 open-label extension study shows sustained benefits of Soliris (Eculizumab) treatment for patients with refractory generalized myasthenia gravis.Says safety profile of Soliris was consistent with that observed in REGAIN study.Says ‍study is ongoing and planned to continue until January 2019​.Says ‍new results show sustained benefits across MG-specific assessment scales through additional 52 weeks for patients who continued to get Soliris​.Says benefits for patients treated with Soliris in REGAIN through 26 weeks were maintained in extension study across all four assessment scales.Says ‍safety profile of Soliris was consistent with that observed in REGAIN study​.Says benefits for patients treated with Soliris in REGAIN through 26 weeks were maintained in extension study.  Full Article

Alexion to reduce 20 pct of its global workforce
Tuesday, 12 Sep 2017 

Sept 12 (Reuters) - Alexion Pharmaceuticals Inc :Alexion announces restructuring to advance corporate strategy.Alexion Pharmaceuticals Inc - ‍global workforce reduction of approximately 20 percent​.Alexion Pharmaceuticals Inc - ‍expect to deliver approximately $270 million in GAAP and approximately $250 million in non-GAAP pre-tax savings annually by 2019​.Alexion Pharmaceuticals Inc - ‍expect to reinvest approximately $100 million annually to build pipeline.Alexion Pharmaceuticals - ‍ Alexion anticipates total pre-tax restructuring, related expenses associated with restructuring to be $340 million to $440 million​.Alexion Pharmaceuticals Inc - plans to relocate its headquarters to Boston, MA by mid-2018.Alexion - ‍expects that increased financial flexibility will allow co to reinvest approximately $100 million a year into research and development starting in 2018​.Alexion Pharmaceuticals Inc - ‍company's 2017 revenue guidance remains unchanged​.Alexion Pharmaceuticals Inc - company plans to have approximately 400 positions in Boston.Alexion Pharmaceuticals Inc - ‍pre-tax restructuring and related expenses of approximately $240 million to $300 million are expected to be recorded in 2017​.Alexion Pharmaceuticals Inc - ‍2017 GAAP EPS guidance will be impacted by restructuring and related expenses, 2017 non-GAAP EPS guidance is unchanged​.Alexion Pharmaceuticals Inc - ‍is right-sizing certain G&A functions, such as human resources, finance and information technology (IT).  Full Article

BRIEF-Alexion Says No Compulsory License Of Soliris Was Requested Or Granted In Brazil

* ALEXION PROVIDES STATEMENT ON SUPERIOR COURT OF JUSTICE (STJ) DECISION IN BRAZIL INVOLVING SOLIRIS® (ECULIZUMAB)